Payment overview · 2025
General Payments
$474.89
23 reported records · 8 companies
Healthcare provider profile · identity verified
Marga B. Ngwang, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · AUSTELL, GA · NPI 1861703654
Verified facts
What the public records show
CMS Open Payments records show Marga B. Ngwang, M.D. received $474.89 in general payments during 2025 across 23 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 38.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $184.14 | 38.8% | 10 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $107.67 | 22.7% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $67.68 | 14.2% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $39.91 | 8.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $26.94 | 5.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.31 | 3.6% | 1 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $16.24 | 3.4% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $15.00 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $474.89 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $291.81 | 14 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $67.68 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $39.91 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $26.94 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $15.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
51 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
64 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1204 | 223 |
| Amlodipine Besylate | Amlodipine Besylate | 1001 | 193 |
| Eliquis | Apixaban | 881 | 91 |
| Gabapentin | Gabapentin | 640 | 117 |
| Levothyroxine Sodium | Levothyroxine Sodium | 491 | 77 |
| Lisinopril | Lisinopril | 468 | 81 |
| Metformin Hcl | Metformin Hcl | 455 | 90 |
| Tamsulosin Hcl | Tamsulosin Hcl | 382 | 73 |
| Pantoprazole Sodium | Pantoprazole Sodium | 357 | 82 |
| Mirtazapine | Mirtazapine | 347 | 68 |
| Metoprolol Tartrate | Metoprolol Tartrate | 326 | 53 |
| Memantine Hcl | Memantine Hcl | 322 | 48 |
| Levetiracetam | Levetiracetam | 306 | 44 |
| Furosemide | Furosemide | 292 | 61 |
| Carvedilol | Carvedilol | 262 | 58 |
| Donepezil Hcl | Donepezil Hcl | 259 | 46 |
| Trazodone Hcl | Trazodone Hcl | 255 | 46 |
| Famotidine | Famotidine | 221 | 47 |
| Quetiapine Fumarate | Quetiapine Fumarate | 220 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 207 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 205 | 41 |
| Hydralazine Hcl | Hydralazine Hcl | 201 | 50 |
| Losartan Potassium | Losartan Potassium | 194 | 47 |
| Sertraline Hcl | Sertraline Hcl | 188 | 48 |
| Divalproex Sodium | Divalproex Sodium | 183 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 173 | 40 |
| Potassium Chloride | Potassium Chloride | 170 | 38 |
| Tramadol Hcl | Tramadol Hcl | 168 | 44 |
| Baclofen | Baclofen | 167 | 29 |
| Montelukast Sodium | Montelukast Sodium | 142 | 24 |
| Omeprazole | Omeprazole | 141 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 139 | 34 |
| Ondansetron Hcl | Ondansetron Hcl | 130 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 124 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 113 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 106 | 33 |
| Oxycodone Hcl | Oxycodone Hcl | 103 | 20 |
| Risperidone | Risperidone | 103 | 13 |
| Clonidine Hcl | Clonidine Hcl | 102 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 101 | 26 |
| Farxiga | Dapagliflozin Propanediol | 100 | 15 |
| Pregabalin | Pregabalin | 98 | 16 |
| Allopurinol | Allopurinol | 95 | 26 |
| Lorazepam | Lorazepam | 94 | 18 |
| Nifedipine Er | Nifedipine | 92 | 20 |
| Latanoprost | Latanoprost | 88 | 21 |
| Olanzapine | Olanzapine | 88 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 85 | 19 |
| Finasteride | Finasteride | 83 | 17 |
| Ibuprofen | Ibuprofen | 81 | 28 |
| Sevelamer Carbonate | Sevelamer Carbonate | 80 | 11 |
| Prednisone | Prednisone | 78 | 35 |
| Galantamine Hbr | Galantamine Hbr | 77 | 14 |
| Januvia | Sitagliptin Phosphate | 77 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 74 | 17 |
| Linzess | Linaclotide | 73 | 14 |
| Spironolactone | Spironolactone | 73 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 72 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 69 | 39 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 68 | suppressed |
| Lacosamide | Lacosamide | 68 | suppressed |
| Galantamine Er | Galantamine Hbr | 65 | 11 |
| Lactulose | Lactulose | 65 | 14 |
| Simvastatin | Simvastatin | 65 | 15 |
| Mounjaro | Tirzepatide | 64 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 63 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 63 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 24 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 60 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 58 | 28 |
| Metformin Hcl Er | Metformin Hcl | 58 | 15 |
| Novolog Flexpen | Insulin Aspart | 58 | 13 |
| Oxcarbazepine | Oxcarbazepine | 57 | suppressed |
| Xarelto | Rivaroxaban | 57 | suppressed |
| Glipizide | Glipizide | 56 | 14 |
| Ondansetron Odt | Ondansetron | 56 | 23 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 55 | 27 |
| Midodrine Hcl | Midodrine Hcl | 54 | 13 |
| Azithromycin | Azithromycin | 53 | 44 |
| Aripiprazole | Aripiprazole | 52 | 11 |
| Alendronate Sodium | Alendronate Sodium | 51 | suppressed |
| Jardiance | Empagliflozin | 51 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | suppressed |
| Meloxicam | Meloxicam | 49 | 11 |
| Warfarin Sodium | Warfarin Sodium | 49 | suppressed |
| Torsemide | Torsemide | 48 | 15 |
| Buspirone Hcl | Buspirone Hcl | 43 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | suppressed |
| Valsartan | Valsartan | 42 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 41 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | 11 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 41 | 19 |
| Brimonidine Tartrate | Brimonidine Tartrate | 40 | suppressed |
| Ezetimibe | Ezetimibe | 40 | 12 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 40 | suppressed |
| Tradjenta | Linagliptin | 40 | suppressed |
| Humalog | Insulin Lispro | 38 | 14 |
| Xifaxan | Rifaximin | 37 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 36 | suppressed |
| Cephalexin | Cephalexin | 36 | 20 |
| Scopolamine | Scopolamine | 35 | suppressed |
| Lamotrigine | Lamotrigine | 34 | suppressed |
| Novolog | Insulin Aspart | 33 | 12 |
| Bumetanide | Bumetanide | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Digoxin | Digoxin | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Methocarbamol | Methocarbamol | 31 | 17 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 16 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 30 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 30 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 28 | 15 |
| Alprazolam | Alprazolam | 28 | suppressed |
| Ertapenem | Ertapenem Sodium | 28 | suppressed |
| Glimepiride | Glimepiride | 28 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 27 | 11 |
| Clonazepam | Clonazepam | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Timolol Maleate | Timolol Maleate | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 26 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 26 | suppressed |
| Valproic Acid | Valproic Acid | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 17 |
| Nystatin | Nystatin | 25 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Ketoconazole | Ketoconazole | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 23 | suppressed |
| Amantadine | Amantadine Hcl | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 19 |
| Anastrozole | Anastrozole | 22 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 11 |
| Dantrolene Sodium | Dantrolene Sodium | 21 | suppressed |
| Glucagon Emergency Kit | Glucagon | 21 | 11 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | 11 |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 14 |
| Levemir | Insulin Detemir | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 12 |
| Enoxaparin Sodium | Enoxaparin Sodium | 19 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Carbamazepine | Carbamazepine | 18 | suppressed |
| Clonidine | Clonidine | 18 | suppressed |
| Dexamethasone | Dexamethasone | 18 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Olanzapine Odt | Olanzapine | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Levocarnitine | Levocarnitine | 17 | suppressed |
| Restasis | Cyclosporine | 17 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 17 | 12 |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 17 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Letrozole | Letrozole | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 12 |
| Ozempic | Semaglutide | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 15 | 15 |
| Ceftriaxone | Ceftriaxone Sodium | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Ingrezza | Valbenazine Tosylate | 15 | suppressed |
| Insulin Aspart | Insulin Aspart | 15 | suppressed |
| Lubiprostone | Lubiprostone | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Teriflunomide | Teriflunomide | 15 | suppressed |
| Trifluoperazine Hcl | Trifluoperazine Hcl | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 12 |
| Sevelamer Hcl | Sevelamer Hcl | 14 | suppressed |
| Tivicay | Dolutegravir Sodium | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 13 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Paliperidone Er | Paliperidone | 13 | suppressed |
| Briviact | Brivaracetam | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Calcium Acetate | Calcium Acetate | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Glatiramer Acetate | Glatiramer Acetate | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Phenytoin | Phenytoin | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Arformoterol Tartrate | Arformoterol Tartrate | 11 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 11 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 11 | suppressed |
| Entacapone | Entacapone | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 11 | suppressed |
| Lumigan | Bimatoprost | 11 | suppressed |
| Ofloxacin | Ofloxacin | 11 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $474.89 · 23 records | Otsuka America Pharmaceutical, Inc. | Cologuard Collection Kit, ImmunoCAP, KISUNLA, Kerendia, LOREEV XR, REPATHA, REXULTI | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error